Synthesis and anti-tubercular activity of 3-substituted benzo[b]thiophene-1,1-dioxides

被引:16
作者
Chandrasekera, N. Susantha [1 ]
Bailey, Mai A. [1 ]
Files, Megan [1 ]
Alling, Torey [1 ]
Florio, Stephanie K. [1 ]
Ollinger, Juliane [1 ]
Odingo, Joshua O. [1 ]
Parish, Tanya [1 ]
机构
[1] Infect Dis Res Inst, TB Discovery Res, Seattle, WA 98102 USA
基金
比尔及梅琳达.盖茨基金会;
关键词
Tuberculosis; Antimicrobial; Benzothiophene dioxide; Drug discovery; Mycobacterium tuberculosis; High throughput screening; Antibacterial;
D O I
10.7717/peerj.612
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
We demonstrated that the 3-substituted benzothiophene-1,1-dioxide class of compounds are effective inhibitors of Mycobacterium tuberculosis growth under aerobic conditions. We examined substitution at the C-3 position of the benzothiophene-1,1-dioxide series systematically to delineate structure-activity relationships influencing potency and cytotoxicity. Compounds were tested for inhibitory activity against virulent M. tuberculosis and eukaryotic cells. The tetrazole substituent was most potent, with a minimum inhibitory concentration (MIC) of 2.6 mu M. However, cytotoxicity was noted with even more potency (Vero cell TC50=0.1 mu M). Oxadiazoles had good anti-tubercular activity (MICs of 3-8 mu M), but imidazoles, thiadiazoles and thiazoles had little activity. Cytotoxicity did not track with anti-tubercular activity, suggesting different targets or mode of action between bacterial and eukaryotic cells. However, we were unable to derive analogs without cytotoxicity; all compounds synthesized were cytotoxic (TC50 of 0.1-5 mu M). We conclude that cytotoxicity is a liability in this series precluding it from further development. However, the series has potent anti-tubercular activity and future efforts towards identifying the mode of action could result in the identification of novel drug targets.
引用
收藏
页数:10
相关论文
共 5 条
[1]   High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv [J].
Ananthan, Subramaniam ;
Faaleolea, Ellen R. ;
Goldman, Robert C. ;
Hobrath, Judith V. ;
Kwong, Cecil D. ;
Laughon, Barbara E. ;
Maddry, Joseph A. ;
Mehta, Alka ;
Rasmussen, Lynn ;
Reynolds, Robert C. ;
Secrist, John A., III ;
Shindo, Nice ;
Showe, Dustin N. ;
Sosa, Melinda I. ;
Suling, William J. ;
White, E. Lucile .
TUBERCULOSIS, 2009, 89 (05) :334-353
[2]   Drugs in Development for Tuberculosis [J].
Ginsberg, Ann M. .
DRUGS, 2010, 70 (17) :2201-2214
[3]   Variation among Genome Sequences of H37Rv Strains of Mycobacterium tuberculosis from Multiple Laboratories [J].
Ioerger, Thomas R. ;
Feng, Yicheng ;
Ganesula, Krishna ;
Chen, Xiaohua ;
Dobos, Karen M. ;
Fortune, Sarah ;
Jacobs, William R., Jr. ;
Mizrahi, Valerie ;
Parish, Tanya ;
Rubin, Eric ;
Sassetti, Chris ;
Sacchettini, James C. .
JOURNAL OF BACTERIOLOGY, 2010, 192 (14) :3645-3653
[4]   A Dual Read-Out Assay to Evaluate the Potency of Compounds Active against Mycobacterium tuberculosis [J].
Ollinger, Juliane ;
Bailey, Mai Ann ;
Moraski, Garrett C. ;
Casey, Allen ;
Florio, Stephanie ;
Alling, Torey ;
Miller, Marvin J. ;
Parish, Tanya .
PLOS ONE, 2013, 8 (04)
[5]  
World Health Organization, 2011, REP GLOB TUB CONTR